ApoE4-carrying Human Astrocytes Oversupply Cholesterol into Neurons and Promote Aβ Generation

Se-In Lee
DGIST: Daegu Gyeongbuk Institute of Science and Technology

Woojin Jeong
DGIST: Daegu Gyeongbuk Institute of Science and Technology

Sukhee Cho
DGIST: Daegu Gyeongbuk Institute of Science and Technology

Hyein Lee
DGIST: Daegu Gyeongbuk Institute of Science and Technology

Yonghee Jang
DGIST: Daegu Gyeongbuk Institute of Science and Technology

Yuan-Ta Lin
MIT: Massachusetts Institute of Technology

Li-Huei Tsai
MIT: Massachusetts Institute of Technology

Jinsoo Seo (jsseo@dgist.ac.kr)
Daegu Gyeongbuk Institute of Science and Technology

Research article

Keywords: Alzheimer's disease, human induced pluripotent stem cells, apolipoprotein E, cholesterol, lipid rafts

DOI: https://doi.org/10.21203/rs.3.rs-122857/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** The onset of Alzheimer’s disease (AD) typically occurs later in life. Recent genetic analysis of patients and unaffected individuals revealed multiple genetic variants associated with late-onset AD. One of the strongest genetic risk factors for AD is ε4 allele of *APOE* encoding apolipoprotein (ApoE), which is predominantly expressed in astrocytes. The role and mechanism of ApoE in initiating AD-associated pathologies, including amyloid-β (Aβ) accumulation and neurodegeneration in neurons, remains to be elucidated.

**Methods:** Human induced pluripotent stem cells (hiPSCs) from healthy individuals and isogenic cells in which the ApoE ε3 allele was replaced with an ε4 allele were selected to generate human neurons and astrocytes. To investigate the effect of astrocytic ApoE4 on neuronal Aβ production, iPSC-derived neurons carrying the ApoE ε3 allele were cultured in conditioned media from healthy iPSC-derived astrocytes (ApoE3/E4 heterozygote) for five weeks. Then, the media were replaced with either ApoE3 or ApoE4 astrocyte conditioned media (ACM), cultured for four days, and neuronal amyloid precursor protein (APP) expression and Aβ production were measured. To determine potential mechanisms for upregulation of APP in neurons by ApoE4 ACM, changes in plasma membrane lipid rafts were investigated by staining for cholera toxin B. Methyl-b-cyclodextrin (MβCD) was applied to deplete cholesterol in ApoE4 ACM.

**Results:** Secretory factors in conditioned media from hiPSC-derived astrocytes carrying APOE4 significantly increased the levels of APP and Aβ secretion in hiPSC-derived neurons. Increasing cholesterol levels in culture media mimicked the effects of ApoE4 ACM by inducing the formation of lipid rafts that potentially provide a physical platform for APP localization on the membrane. We further found that reducing cholesterol levels in ApoE4 ACM with MβCD abolished its effects on neuronal lipid raft expansion and Aβ generation.

**Conclusions:** Our study suggests that ApoE4 astrocytes contribute to amyloidosis by the expansion of lipid rafts and facilitate neuronal Ab production through oversupply of cholesterol.

**Background**

Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder that accounts for the majority of cases of dementia [1]. One of the major hallmarks of AD is the accumulation of amyloid-β (Aβ) in the brain [2, 3]. Aβ is a fragment peptide derived from amyloid precursor protein (APP), which is highly expressed in neurons and is known to be important for neuronal development and function [2]. Aβ levels in the brain are tightly regulated by the balance between its production and clearance [3, 4], and although Aβ can be generated by non-neuronal cells, it is thought to be primarily produced by neurons under typical physiological conditions [2, 5]. To maintain a homeostatic environment, generated Aβ is taken up by glial cells, such as astrocytes and microglia, to be degraded [4, 5].

Genome-wide association studies have identified novel genetic risk factors associated with AD, even in late-onset AD (LOAD) cases. In contrast with genetic variants in familial cases, many LOAD-associated
variants are located in genes known to be enriched in glial cells [4, 7]. The precise AD-related phenotypes induced by these variants, and the mechanisms by which they arise, remain to be elucidated. Moreover, the reason as to why the timing of disease onset by these genetic factors is later than that induced by familial mutations located in APP, PSEN1, or PSEN2 remains uncertain.

APOE4 is one of the strongest genetic risk factors for LOAD [6]. ApoE is an apolipoprotein encoded by the APOE gene on chromosome 19, and is well known for its function in lipid transport by formation of lipoprotein complexes. In the central nervous system, ApoE is produced primarily by astrocytes, and its expression is upregulated in microglia under neurodegenerative conditions [7, 8]. There are three genotypes for ApoE in humans, including ApoE2, ApoE3, and ApoE4. Each genotype produces proteins that are considered to have structural differences according to amino acid sequences at 112 and/or 158 (ApoE2 - Cys112, Cys158; ApoE3 - Cys112, Arg158; ApoE4 - Arg112, Arg158) [9]. Although the difference in their sequence appears subtle, the translated proteins result in a significant difference in the risk for AD. While the ε2 allele is known to be protective, bearing ε4 increases the risk of AD [9, 10].

A previous study using human induced pluripotent stem cells (iPSCs) from ApoE4 carriers suggested that ApoE4 contributes to amyloidosis by increasing Aβ secretion in ApoE4 neurons and decreasing Aβ clearance in ApoE4 astrocytes [11, 12]. However, the involvement and mechanisms by which ApoE4 astrocytes contribute to neuronal Aβ production remains to be determined. Here, using hiPSC-derived astrocytes and neurons carrying ApoE3 or ApoE4, we aimed to investigate whether ApoE4 astrocytes regulate neuronal Aβ production and if this regulation is mediated by abnormal cholesterol supply by ApoE4 astrocytes.

**Methods**

**iPSCs culture**

The use of human iPSCs was approved by the Institutional Review Board (IRB) of Daegu Gyeongbuk Institute for Science and Technology (Permit Number: DGIST-190829-BR-071-01). ApoE3 iPSC line is generated from the Coriell Institute's fibroblast line derived from healthy individuals (age 75, female; #AG09173) by Dr. Yankner Laboratory at Harvard Medical School [13]. ApoE4 isogenic line is generated from this ApoE3 iPSC line as previously described [11]. For ApoE3/E4 heterozygous astrocyte conditioned media (ACM), an iPSC line derived from a healthy individual (age 22, female; #GM23720) was obtained from the Coriell Institute. iPSCs were maintained on matrigel (Corning 354277)-coated plate in mTeSR1 media (Stemcell) at 37 °C with 5% CO₂ conditioned incubator.

**Neural progenitor cells differentiation**

The iPSCs were cultured with mTeSR1 media on the matrigel coated 6-well plate. When cell density was 100% confluent, the media was replaced with neuronal induction media [DMEM/F-12 GlutaMAX (Gibco), Neurobasal (Gibco), 0.5x N-2(Gibco), 0.5x B27(Gibco), 0.5x GlutaMAX (Thermo Fisher Scientific), 5 μg/ml insulin (Sigma-Aldrich), 0.5x NEAA (Thermo Fisher Scientific), 100 μM 2-mercaptoethanol (Sigma-
Aldrich), 1x Penicillin/Streptomycin (Gibco)] with 1 µM Dorsomorphin (Tocris) and 10 µM SB431542 (Tocris) for 11 days. Then, cells were transferred to a new Matrigel-coated plate. When the neural rosette is apparent, cells were transferred to the new plate at the density of $5 \times 10^6$. Cells were then fed with neuronal induction media containing 20 ng/ml FGF2 (Peprotech).

**Astrocyte differentiation**

hiPSC-derived astrocytes were generated as described previously [14]. Briefly, NPCs were seeded at 1.5 x $10^5$ cells/well in a 6-well plate. The next day, neuronal induction media were replaced with Astrocyte Media (Sciencell). AM was changed every 2 days. After 4 weeks of differentiation, cells were suspended with TrypLE (Gibco) and sorted with an anti-GLAST-PE antibody (Miltenyl Biotec) using a flow cytometer (Sony SH800). The identity of sorted astrocytes was confirmed by immunocytochemistry with anti-GFAP and anti-AQP4 antibodies. ACM were prepared by culture of astrocytes with Neurobasal, 1 x GlutaMAX, 0.5x N-2, 0.5x B-27 (without vitamin A), BSA (Thermo Fisher Scientific).

**Neuron differentiation**

Neurons were differentiated from hiPSCs as previously described [11]. Briefly, hiPSCs were seed on a matrigel-coated 6-well plate at a density of $4 \times 10^6$/well with mTeSR1 media containing 20 µM ROCK inhibitor Y-27632 (Tocris). After 1.5 hr, lentivirus with TetO-NGN2-GFP-puro and rtTA expressing vectors were treated. Next day, media was replaced with neuronal differentiation media [DMEM/F12(Gibco), 1x N2, 1x NEAA] with 10 ng/ml BDNF (Peprotech), 10 ng/ml NT-3 (Peprotech), 0.2 µg/ml laminin (Corning) and 2 µg/ml doxycycline (Sigma-Aldrich). Two days later, media was fully changed with media [Neurobasal (Gibco), 1x B27, 1x GlutaMAX] containing 1 µg/ml puromycin (Millipore), 10 ng/ml BDNF, 10 ng/ml NT-3, 0.2 µg/ml laminin and 2 µg/ml doxycycline. After 2 days, cells were transferred to a matrigel-coated 24-well plate at a density of $1.5 \times 10^5$/well. The next day, media was replaced with ACM containing 1 µM Ara-C (Sigma-Aldrich). Three days later, media were replaced with ACM containing 10 ng/ml BDNF, 10 ng/ml NT-3, 0.2 µg/ml laminin and 0.5 µg/ml doxycycline. Half volume of media was replaced with fresh media every 4 days, and cells were used for experiments at 5 weeks of differentiation.

**Rat primary hippocampal neuron culture**

One day before rat primary hippocampus culture, coverslips were coated with 0.1% Poly-D-Lycine (Sigma-Aldrich). Hippocampi were isolated from embryonic day-18 embryos. Isolated hippocampi were collected in HBSS (Thermo), and incubated in papain solution [1 mM CaCl$_2$, 0.5 mM EDTA, Papain (Worthington Biochemical), 1x HBSS] at 37˚C for 15 min. After incubation, tissues were washed with HBSS solution and gently agitated to single cells in neuron culture media [Neurobasal media, 1x GlutaMAX, 1x sodium pyruvate (Sigma-Aldrich), 1x B-27, 1x Penicillin-Streptomycin (Gibco), 0.5% FBS (Gibco)]. Neurons were used for experiments at DIV 17.

**Drug treatment**

Neurons were treated with 20 µM cholesterol (Calbiochem) for 4 days or 300 µM methyl-β-cyclodextrin (MβCD, Merck) for 1 day.
Western blotting

Proteins were extracted from ACM-treated neurons with RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Concentration of proteins was measured by the Bradford assay kit (Bio-Rad). Lysates were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membrane (Bio-Rad), and proved with the indicated antibodies.

Filipin III staining

Neurons were fixed with 4% PFA (Biosesang), then cholesterol staining kit (Biovision) was used for filipin III staining. Based on the manufacturer’s instruction, neurons were washed with assay buffer, and incubated with filipin staining solution (1:100 diluted in assay buffer) for 1 hr at room temperature. Then, cells were washed with assay buffer three times and mounted for imaging.

Immunocytochemistry

Cells were briefly washed with cold DPBS and fixed with 4% PFA solution at room temperature for 15 minutes. After fixation, cells were washed with cold DPBS three times and incubated with CTX-B (Invitrogen) for 30 minutes in dark at room temperature. Cells were washed with DPBS three times and permeabilized with 0.1% Triton-X (Thermo Fisher Scientific) in PBS for 10 min. Then, cells were incubated in blocking buffer [0.1% Tween 20 (Promega), 10% normal donkey serum (Merck), 2% BSA (Gemini Bio), 1M glycine (Sigma-Aldrich)] for 1hr at room temperature. Primary antibodies were diluted in blocking buffer, and cells were incubated at 37°C for 1 hr. After 3 times of washing, secondary antibodies diluted in blocking buffer were treated to cells for 1 hr at room temperature. Washed cells were further incubated with Hoechst 33342 for nucleus staining and mounted for imaging.

Microscopy

The LSM 800 confocal microscope (Zeiss) was used for imaging, and the Zen software (Zeiss) and Image J (NIH) were used for data analysis.

Aβ ELISA

Human Aβ40 or Aβ42 ELISA detection kit (Thermo Fisher Scientific) was used to detect secreted Aβ40 or Aβ42 based on the manufacturer’s instruction. The absorbance was detected with the microplate reader SpectraMax plus 384 (Molecular Devices) at 450 nm wavelength.

Antibodies

APP (Abcam), GAPDH (Santa Cruz Biotechnology), CTX-B (Invitrogen), GFAP (Abcam), AQP4 (Merck), Synaptophysin (Sigma-Aldrich), PSD95 (Thermo Fischer Scientific), Hoechst 33342 (Thermo Fischer Scientific), Secondary antibodies (Jackson ImmunoResearch).

Statistical analysis
The Prism 8 (GraphPad) was used for statistical analysis. Unpaired Student’s t-test or one-way ANOVA test with Dunnett’s post hoc analysis was used for normal distribution, while the Kruskal-Wallis test was performed for non-normal distribution.

Results

ApoE4 astrocyte-conditioned media increased APP expression and Aβ42 secretion in hiPSC-derived neurons

To address the effect of ApoE4 astrocytes on neuronal APP expression and Aβ generation, we utilized an iPSC line derived from healthy individuals carrying the ApoE3 allele and its isogenic line in which ApoE3 is converted to ApoE4 [11]. Both ApoE3 and ApoE4 iPSC lines were differentiated in astrocytes or excitatory neurons as described previously [14, 15] with some modifications (Fig. 1A), and immunostaining confirmed the identity of these cells (Supplementary Fig. 1). In order to investigate whether secretory factors from ApoE4 astrocytes could affect neuronal Aβ production, we generated healthy hiPSC-derived neurons carrying ApoE3 and cultured them in conditioned media from other healthy iPSC-derived astrocytes (ApoE3/E4 heterozygote) for five weeks. The media were then replaced with either ApoE3 or ApoE4 astrocyte conditioned media (ACM) and cultured for four days (Fig. 1B). We found that ApoE4 ACM positively regulated the expression of APP in hiPSC-derived neurons carrying ApoE3 (Fig. 1C, D). Immunoblotting from neuronal lysates revealed that APP levels were significantly increased by ApoE4 ACM (Fig. 1E). We further measured the secreted levels of Aβ40 and Aβ42 and found that Aβ42 secretion was significantly increased by ApoE4 ACM. These data show that secretory factors from ApoE4 astrocytes positively regulate neuronal APP expression and Aβ secretion.

Cholesterol positively regulated the formation of lipid rafts and APP expression in hiPSC-derived neurons

Accumulation of intracellular cholesterol in hiPSC-derived ApoE4 astrocytes compared to isogenic ApoE3 astrocytes has been recently reported [11, 16], and Lin et al. further reported increased cholesterol secretion from ApoE4 astrocytes. Astrocytes supply cholesterol to neurons to support synapse formation and regulate membrane fluidity [9, 17]. Moreover, cholesterol, along with ganglioside and triglyceride, is a critical component of membrane lipid rafts, which provide a suitable platform for various membrane-bound proteins, including glutamate receptors. APP and its processing secretases, β- and γ-secretase, are also known to be located in lipid rafts, while α-secretase is mainly expressed in non-lipid rafts [18, 19].

Previous studies have shown that increasing cholesterol in the membrane induced the formation of lipid rafts and increased Aβ production [20, 21]. Therefore, we hypothesized that increased levels of cholesterol in ApoE4 ACM could be a key factor in upregulating APP and its processing by facilitating the formation of lipid rafts. First, the conditions were optimized to regulate environmental cholesterol levels.
by treating neurons with cholesterol or methyl β-cyclodextrin (MβCD; to deplete cholesterol) in a rat primary neuron culture system (Supplementary Fig. 2A). We found that treatment with 20 µM of cholesterol for four days was sufficient to increase neuronal cholesterol, as visualized by filipin III staining, which is naturally fluorescent upon cholesterol binding (Supplementary Fig. 2B, C). We then measured the levels of lipid rafts by staining for cholera toxin B (CTX-B), a well-known lipid raft marker, and found a significant increase in lipid rafts following cholesterol treatment (Supplementary Fig. 2D-E). APP expression was also increased in cholesterol-treated rat primary neurons (Supplementary Fig. 2F). There was no reduction in both neuronal cholesterol and lipid rafts following MβCD treatment in rat primary neurons (Supplementary Fig. 2B-E), which could be due to the homeostatic mechanism of neurons to compensate for the loss of intracellular cholesterol. To address whether cholesterol treatment is sufficient to mimic the effect of ApoE4 ACM on neuronal APP expression and Aβ secretion, as shown in Fig. 1C-F, we treated hiPSC-derived neurons with cholesterol or MβCD (Fig. 2A). The upregulation of cholesterol in neurons by exogenous cholesterol treatment was confirmed by filipin III staining (Fig. 2B, C). Consistent with the observation in rat primary neurons, MβCD treatment did not alter the levels of cholesterol in hiPSC-derived neurons (Fig. 2B, C). We then measured levels of lipid rafts in neurons and found that cholesterol treatment increased the area of CTX-B signals without affecting intensity, suggesting the expansion of lipid rafts (Fig. 2D, E). We also measured APP levels in neurons and found significant upregulation of APP expression by cholesterol treatment, due to increased area of APP signals rather than intensity (Fig. 2F), which is consistent with rat primary neurons treated with cholesterol (Supplementary Fig. 2F). We further found that the co-localization of APP and CTX-B was significantly increased by cholesterol treatment in both hiPSC-derived neurons and rat primary neurons (Fig. 2G, Supplementary Fig. 2G). To determine whether APP upregulation is caused simply by the expansion of lipid rafts or if more APP is recruited to the given area of lipid rafts, we measured the intensity of APP in the CTX-B/APP co-localized area. The data showed that there was no alteration in APP intensity in these regions (Fig. 2G, Supplementary Fig. 2G), suggesting that increased APP expression by extracellular cholesterol supply is mainly due to the increased area of lipid rafts.

**Cholesterol in ApoE4 ACM increased the formation of lipid rafts in hiPSC-derived neurons**

To investigate whether the effects of ApoE4 ACM on neuronal cholesterol levels and lipid raft formation were due to cholesterol oversupply, we measured cholesterol levels in ApoE3 and ApoE4 ACM. Consistent with a previous report [11], we found higher cholesterol levels in ApoE4 ACM than in ApoE3 ACM (Fig. 3A). We then measured filipin III in hiPSC-derived neurons cultured with conditioned media from either ApoE3 or ApoE4 astrocytes as described in Fig. 1B, and ApoE4 ACM-treated neurons displayed increased filipin III signals (Fig. 3B, C). We also found that the area and total levels of CTX-B were significantly increased compared to those of ApoE3 ACM-treated neurons (Fig. 3D-E). To determine whether the cholesterol in ApoE4 ACM is the major cause of the upregulation of lipid rafts and APP in neurons, we added MβCD to ApoE4 ACM during neuronal culture (Fig. 3F) and found that the upregulation of neuronal cholesterol by
ApoE4 ACM was significantly attenuated by MβCD, potentially due to its scavenging effect toward exogenous cholesterol (Fig. 3G, H). The addition of MβCD to ApoE4 ACM abolished the ApoE4 ACM-induced increase in lipid raft expansion (Fig. 3I, J).

**Reducing cholesterol attenuated ApoE4 ACM-induced APP upregulation and Aβ_{42} secretion in hiPSC-derived neurons**

To determine whether cholesterol in ApoE4 ACM was the major cause for the upregulation of APP and its metabolism to produce Aβ in hiPSC-derived neurons, we added MβCD to ApoE4 ACM during neuronal culture (Fig. 4A). As shown in Fig. 1E, neurons cultured with ApoE4 ACM showed increased expression of APP compared to those cultured with ApoE3 ACM. However, in the presence of MβCD, ApoE4 ACM was not able to induce significant upregulation of APP. Increased co-localization of lipid rafts and APP by ApoE4 ACM was also abolished in neurons treated with MβCD (Fig. 4B-E). Furthermore, MβCD treatment inhibited the ApoE4 ACM-induced increase in Aβ_{42} secretion in hiPSC-derived neurons (Fig. 4F). Taken together, these data suggest that an excess supply of cholesterol is responsible for ApoE4 ACM-mediated neuronal Aβ_{42} overproduction.

**Discussion**

Abnormal neuronal cholesterol levels have been linked to AD-related pathology both *in vitro* and *in vivo*. For example, increased levels of cholesterol were observed in AD brain samples, and the severity of pathology was correlated with cholesterol levels [22, 23]. Inhibition of cholesterol efflux by reducing expression of CYP46A1, a cholesterol 24S-hydroxylase, in a neuron-specific manner was shown to result in cognitive deficits and neuronal death in wild-type mice. The study further showed the recruitment of APP to lipid rafts and Aβ upregulation prior to neuronal death in both wild-type and APP23 mice [24]. Here, we showed that ApoE4 bearing astrocytes increased cholesterol supply to neurons, leading to the upregulation of APP and Aβ secretion in a paracrine manner. Application of cholesterol recapitulated the effects of ApoE4 ACM on neurons, and the effects of ApoE4 ACM were abolished by MβCD. These data revealed the major contribution of secretory cholesterol from ApoE4 astrocytes to lipid raft expansion and APP expression, which promotes Aβ_{42} secretion in neurons.

A recent study showed that CHO cell lines expressing familial AD-associated PSEN1 ΔE9 display increased levels of cholesterol, which leads to the enrichment of APP in lipid rafts [25]. Similarly, a previous study suggested binding between cholesterol and β-secretase-derived APP C-terminal fragment (β-CTF) [26]. These data suggest the active role of cholesterol in recruiting APP to lipid rafts. Here, we found that cholesterol oversupply by ApoE4 astrocytes increases the levels of APP in lipid rafts. Although we did not find a difference in APP intensity (local clustering density) in lipid rafts by extracellular cholesterol supply (Fig. 2G and Supplementary Fig. 2G), neurons cultured in ApoE4 ACM displayed...
increased APP intensity in lipid rafts, which was abolished by MβCD treatment (Fig. 4D). As cholesterol was shown to increase the proximity between APP and β-secretase 1 (BACE1) in the membrane [27], further studies are required to examine the expression pattern of β- and γ-secretases on lipid rafts in neurons when they are cultured with ApoE3 or ApoE4 ACM.

Cholesterol was also shown to increase Aβ production through the facilitation of APP endocytosis to endosomes [20]. The low pH environment in endosomes increases BACE1 activity to facilitate APP cleavage and produce β-CTF. Increased size and/or number of early endosomes were found in the brains of AD patients as well as in multiple AD model systems. Moreover, cholesterol loading to the neuronal plasma membrane was shown to result in enlarged endosomes [21]. In the current study, for the first time, we revealed the impact of ApoE4 astrocytes on neuronal cholesterol and lipid rafts that affect Aβ production. Further studies are required to determine whether astrocytic ApoE4 regulates APP processing only in lipid rafts or in endosomal compartments, that is whether cholesterol only affects membrane-originated Aβ production and/or facilitates APP endocytosis and subsequent Aβ generation in endosomes.

Lipid rafts provide a platform for various neuronal membrane proteins and are important for synaptic functions [28]. Previously, cholesterol was shown to promote synapse maturation, whereas depletion of cholesterol significantly reduced lipid raft domain and synapses [28, 29]. The positive correlation between neuronal activity and Aβ production has been supported by multiple studies [30, 31], and the expansion of lipid rafts by ApoE4 ACM could also contribute to the upregulation of Aβ by increasing neuronal activity.

In addition to Aβ production, Aβ clearance can be manipulated by the ApoE4 ACM. Cholesterol accumulation in cellular organelles such as lysosomes has been found to increase intracellular Aβ levels [32]. Therefore, it would be interesting to determine whether increased cholesterol supply from ApoE4 astrocytes induces lysosomal cholesterol accumulation and impairs lysosomal activity and Aβ degradation in neurons.

**Conclusion**

ApoE4, the strongest genetic risk factor for LOAD, has recently been shown to have detrimental effects on astrocytes, including endocytic defects and impaired homeostatic functions [11, 33, 34]. It is not clear, however, whether altered astrocytic properties could affect neighboring neurons and induce AD-associated pathology. Here, we revealed that ApoE4 astrocytes could regulate neuronal APP metabolism to initiate amyloidosis through cholesterol oversupply (Fig. 5). This study provides new insight into the contribution of ApoE4 and astrocytes to amyloidosis in AD, and the importance of regulating astrocytic ApoE isotypes.

**Abbreviations**
ACM: astrocyte conditioned media; AD: Alzheimer's disease; ApoE: apolipoprotein E; APP: amyloid precursor protein; CTX-B: cholera toxin B; GWAS: genome-wide association study; hiPSC: human induced pluripotent stem cells; LOAD: late-onset Alzheimer's disease; MβCD: Methyl-b-cyclodextrin

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declared that they have no competing interests.

Funding

This work was supported by the NIH grant (NIA RF1AG062377) to L.-H.T. and the National Research Foundation of Korea (NRF) grants (2018M3C7A1056275, 2019R1C1C1008591) funded by the Ministry of Science, ICT and Future Planning, and the POSCO Science Fellowship of POSCO TJ Park Foundation to J.S.

Author contributions

SL and WJ performed most of the experiments and analyzed data. SC and HL generated and cultured iPSC-derived astrocytes. YJ generated and cultured iPSC-derived neurons. YTL and LHT provided resources. SL, WJ, and JS conceptualized the project. SL, WJ, SC, and JS wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank all members of the Seo lab for fruitful advice and discussions.

References

1. 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020;16:391–460.
2. O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. Annual Reviews; 2011;34:185–204.
3. De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016;164:603–15.
4. Canter RG, Penney J, Tsai L-H. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature. Nature Publishing Group; 2016;539:187–96.
5. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. Nature Publishing Group; 2009;10:333–44.
6. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. Nature Publishing Group; 2019;51:414–30.
7. Liu C-C, Zhao N, Fu Y, Wang N, Linares C, Tsai C-W, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017;96:1024–1032.e3.
8. Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, Fatimy El R, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. Elsevier Inc; 2017;47:566–9.
9. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.
10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. American Association for the Advancement of Science; 1993;261:921–3.
11. Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J, et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018;98:1141–7.
12. Wang C, Najm R, Xu Q, Jeong D-E, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med. Nature Publishing Group; 2018;24:647–57.
13. Meyer K, Feldman HM, Lu T, Drake D, Lim ET, Ling K-H, et al. REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer's Disease. Cell Rep. 2019;26:1112–9.
14. TCW J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, et al. An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2017;9:600–14.
15. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785–98.
16. TCW J, Liang SA, Qian L, Pipalia NH, Chao MJ, Shi Y, et al. Cholesterol and matrisome pathways dysregulated in human APOE ε4 glia. bioRxiv. Cold Spring Harbor Laboratory; 2019;99:713362.

17. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. The Company of Biologists Ltd; 2012;5:746–55.

18. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease—targeting APP processing in lipid rafts. Nat Clin Pract Neurol. 2007;3:374–82.

19. Raffai RL, Weisgraber KH. Cholesterol: from heart attacks to Alzheimer's disease. J. Lipid Res. American Society for Biochemistry and Molecular Biology; 2003;44:1423–30.

20. Cossec J-C, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossi J, et al. Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. Elsevier; 2010;1801:846–52.

21. Marquer C, Laine J, Dauphinot L, Hanbouch L, Lemercier-Neuillet C, Pierrot N, et al. Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. Mol Neurodegener. BioMed Central; 2014;9:1–13.

22. Lazar AN, Bich C, Panchal M, Desbenoit N, Petit VW, Touboul D, et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 2013;125:133–44.

23. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. National Academy of Sciences; 2004;101:2070–5.

24. Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bièche I, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain. 2015;138:2383–98.

25. Cho YY, Kwon O-H, Park MK, Kim T-W, Chung S. Elevated cellular cholesterol in Familial Alzheimer's presenilin 1 mutation is associated with lipid raft localization of β-amyloid precursor protein. Lakshmana MK, editor. PLoS ONE. Public Library of Science; 2019;14:e0210535.

26. Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, et al. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry. American Chemical Society; 2008;47:9428–46.

27. Marquer C, Devauges V, Cossec J-C, Liot G, Lécart S, Saudou F, et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. Federation of American Societies for Experimental Biology Bethesda, MD, USA; 2011;25:1295–305.

28. Hering H, Lin C-C, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 2003;23:3262–71.

29. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354–7.
30. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 2011;14:750–6.

31. Das U, Scott DA, Ganguly A, Koo EH, Tang Y, Roy S. Activity-Induced Convergence of APP and BACE-1 in Acidic Microdomains via an Endocytosis-Dependent Pathway. Neuron. Elsevier Inc; 2013;79:447–60.

32. Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J. Biol. Chem. American Society for Biochemistry and Molecular Biology; 2001;276:4454–60.

33. Narayan P, Sienski G, Bonner JM, Lin Y-T, Seo J, Baru V, et al. PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4. Cell Rep. 2020;33:108224.

34. Fernandez CG, Hamby ME, McReynolds ML, Ray WJ. The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer’s Disease. Front Aging Neurosci. Frontiers; 2019;11:14.